Context
Results of comparative genomic hybridization studies have suggested that rare copy number variations (CNVs) at numerous loci are involved in the cause of mental retardation, autism spectrum disorders, and schizophrenia.
Objectives
To provide an estimate of the collective frequency of a set of recurrent or overlapping CNVs in 3 different groups of cases compared with healthy control subjects and to assess whether each CNV is present in more than 1 clinical category.
Design
Case-control study.
Setting
Academic research.
Participants
We investigated 28 candidate loci previously identified by comparative genomic hybridization studies for gene dosage alteration in 247 cases with mental retardation, in 260 cases with autism spectrum disorders, in 236 cases with schizophrenia or schizoaffective disorder, and in 236 controls.
Main Outcome Measures
Collective and individual frequencies of the analyzed CNVs in cases compared with controls.
Results
Recurrent or overlapping CNVs were found in cases at 39.3% of the selected loci. The collective frequency of CNVs at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test). Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
Conclusions
Weakly to moderately recurrent CNVs (transmitted or occurring de novo) seem to be causative or contributory factors for these diseases. Most of these CNVs (which contain genes involved in neurotransmission or in synapse formation and maintenance) are present in the 3 pathologic conditions (schizophrenia, autism, and mental retardation), supporting the existence of shared biologic pathways in these neurodevelopmental disorders.
The development of microarray-based technologies for comparative genomic hybridization (array-CGH) analysis has enabled the detection of submicroscopic microdeletions or microduplications, also referred to as copy number variations (CNVs). Recently, this approach has been widely used in neurologic and psychiatric disorders, including mental retardation (MR),1-3 autism spectrum disorders (ASDs),4-7 and schizophrenia.8-11 Findings from these studies suggested that several genes involved in similar neurodevelopmental pathways may be associated with these conditions. However, so far only rare structural variants, sometimes present in a single case, have been identified. Therefore, it is difficult to decipher which of these variations are causative, which are risk factors, and which are only rare polymorphisms unrelated to any pathologic phenotype. De novo rearrangements are usually considered pathogenic, but this argument (which is acceptable for rare large rearrangements detectable by conventional cytogenetics) should be considered with caution for smaller CNVs, for which a high mutation rate is expected. Indeed, it has been estimated that a de novo segmental deletion occurs in 1 per 8 newborns and a de novo segmental duplication in 1 per 50 newborns, with most of these rearrangements being benign polymorphic variants.12 Therefore, the disease association of CNVs has to be tested systematically by comparing the frequency of each candidate CNV in cases and in healthy control subjects. Given the low frequency of each CNV, this would require the study of huge series, achievable only in the context of forthcoming meta-analyses. Other problems arise because ascertainment of most of the published samples, initially recruited for linkage studies, is biased toward multiplex cases and because control samples, when present, are generally composed of subjects not screened for the studied pathologic conditions. The objectives of the present study were (1) to provide an estimate of the collective frequency of a set of recurrent or overlapping CNVs in 3 different groups of cases compared with controls and (2) to assess whether each CNV is present in more than 1 clinical category.
Ascertainment and diagnoses
Cases with schizophrenia and cases with MR were ascertained at University Hospital, Rouen, France, from consecutive hospitalizations in patients with schizophrenia or from consecutive referrals for phenotypic and genetic investigations in patients with intellectual disability. The ASD sample included cases ascertained from consecutive consultations at 4 units specializing in autism diagnosis and evaluation located in Rouen, Tours, and Dijon (France) and in Messina (Italy), as well as cases directly referred by the French Autism Foundation. Controls, all ascertained at University Hospital, Rouen, were screened using a standardized data sheet derived from the Schedule for Affective Disorders and Schizophrenia13 and were required to be free of any psychotic disorder or MR themselves or in their first-degree relatives. All psychiatric diagnoses were established according to DSM-IV criteria following review of case notes and direct examination of cases. The Schedule for Affective Disorders and Schizophrenia13 was used for the clinical assessment of all cases with schizophrenia or schizoaffective disorder. The Autism Diagnostic Interview–Revised,14 the Autism Diagnostic Observation Schedule–Generic,15 or the Childhood Autism Rating Scale16 was used for 83.0% of cases with ASDs (100.0% of cases having ASDs with CNVs). Evaluation of IQs was performed using standardized neuropsychological tests (ie, validated mental age–appropriate Weschler scales [Wechsler Preschool and Primary Scale of Intelligence, Wechsler Intelligence Scale for Children, or Wechsler Adult Intelligence Scale]).
The schizophrenia group included 189 cases with schizophrenia and 47 cases with schizoaffective disorder. Postmorbid IQs were available for two-thirds of cases with schizophrenia; 18.0% of these cases had an IQ lower than 70. The ASD group included 257 cases with autism and 3 cases with Asperger syndrome. The MR group included 235 cases with MR and 12 cases with developmental language disorder. All cases with MR and two-thirds of cases with ASDs were examined by an experienced clinical geneticist (A.G., V.D.-G., V.L., F.B.-B., S.O., L.F., or G.D.R.) and were screened for fragile X mutation and karyotype abnormalities. Cases with large chromosomal anomalies, fragile X syndrome, or other established syndromes were excluded. Cases with common environmental causes of MR such as fetal alcohol syndrome or birth complications were also excluded. Additional clinical features, including intrauterine or postnatal growth retardation and dysmorphic features or malformations, were present in 8.5% of cases with ASDs and in 62.0% of cases with MR. Demographic characteristics of the sample, including 979 unrelated white non-Hispanic subjects from France or Italy, are summarized in Table 1.
After written informed consent, blood samples were drawn from all included participants and whenever possible from parents and affected relatives of cases. Ethics committee approval was obtained from all regions where families were recruited.
Candidate genes and analysis by quantitative multiplex polymerase chain reaction of short fluorescent fragments
A MEDLINE search using the terms CNV, schizophrenia, autism, and mental retardation allowed us to select nonexhaustively a set of 28 loci with microrearrangements characterized by prior array-CGH analyses, often in a single case. This set included major candidate CNV loci identified in cases with ASDs and schizophrenia before April 2008, as well as 8 functionally related CNV loci identified in MR (Table 2). Each locus generally contained a single disease–associated CNV, but in some cases, overlapping CNVs with different boundaries had been described in cases. The gene content of these loci ranged from 1 to 28. At each locus, at least 1 candidate gene had been previously suggested in the seminal studies and was retained for the present analysis. Functionally, most of these candidate genes can be classified in 2 main categories related to synapse formation and maintenance or to neurotransmission.
Copy number variation at each locus was assessed by quantitative multiplex polymerase chain reaction (PCR) of short fluorescent fragments (QMPSF), a method based on the simultaneous amplification of several short genomic fragments under quantitative conditions.44 For each locus, amplicons were designed in the coding sequence of selected candidate genes. All assays were grouped in 3 multiplex PCR experiments that included 10 short genomic fragments (range, 100-301 base pair) each. Primer sequences and PCR conditions are summarized in eTable 1(http://www.archgenpsychiatry.com. DNA fragments generated by QMPSF were separated on a sequencer (ABI Prism 3100; Applied Biosystems, Norwalk, Connecticut), and the resulting fluorescence profiles were analyzed using commercially available software (Gene Scan 3.7 software; Applied Biosystems). For each case, the QMPSF profile was superimposed on that generated from a control by adjusting the same level that the peak obtained for a control amplicon corresponding to a short exonic fragment of the PBGD gene. When a CNV was detected, further analyses aiming to confirm and delineate the size of the rearrangements were performed using additional dedicated QMPSF assays (eFigure 1), array-CGH, or fluorescence in situ hybridization analyses.
Oligonucleotide array-cgh
Oligonucleotide array-CGH was performed using a commercially available array (human genome CGH microarray 4 × 44 K) (Agilent Technologies, Santa Clara, California). This array contains 60-mer oligonucleotide probes (n = 44 290) covering the whole genome, with a mean spatial resolution of approximately 30 to 35 kilobases (kb). Eighty-four percent of the probes reside in intragenic regions, and more than 30 000 genes are each represented by at least 1 probe. All experiments were performed using the June 2006 version of the protocol (version 4.0, Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis; Agilent Technologies).
Fluorescence in situ hybridization
Fluorescence in situ hybridization analyses were performed on metaphase spreads obtained from peripheral lymphocytes from the cases. Selected human genomic bacterial artificial chromosome clones were obtained from a distribution center (BACPAC Resources Center, Oakland, California [http://bacpac.chori.org]).
Dna sequencing and paternity checking
Sequence analysis of the coding exons of the PRODH (OMIM_606810)) gene was performed using primers and PCR conditions previously described45 via an automated sequencer (model 3100; Applied Biosystems). Paternity was checked by microsatellite typing.
Determination of plasma proline level
Plasma proline levels in cases were determined after overnight fasting. All samples were analyzed using ion exchange chromatography (LC 3000 system; Biotronik, Maintal, Germany).
Categorical variables were compared using the Fisher exact test. Two hypotheses were tested. First, the distribution of the collective set of recurrent or overlapping CNVs found in each disease group of cases was compared with that found in controls (3 tests). Second, the distribution of each recurrent or overlapping CNV present in our population was compared between each disease group of cases and controls (33 tests). P values are reported without Bonferroni correction.
Among 743 cases, the proportion of recurrent or overlapping CNVs identified among 28 selected loci (Table 2) was 11 of 28 (39.3%). Their collective frequency was 10 per 236 cases with schizophrenia (4.2%), 16 per 260 cases with ASDs (6.2%), and 13 per 247 cases with MR (5.3%) vs 1 per 236 controls (0.4%), demonstrating a significant excess of these CNVs in each disease group compared with controls (P = .01, P < .001, and P = .001, respectively, Fisher exact test) (Table3, eTable 2, and eTable 3). None of the cases had more than 1 of the 28 CNVs. Only 1 CNV identical to a previously described disease-associated CNV (ie, a 350-kb deletion located at 22q11 spanning the PRODH and DGCR6 (OMIM_601279)) genes)17 was detected in the control group. This deletion, present in a single control, had a low frequency (1 per 236 controls) similar to that previously reported in Japanese46 and Canadian47 populations. Individual significance for the association with ASDs was reached for this PRODH/DGCR6 deletion (9 per 260 cases with ASDs vs 1 per 236 controls [P = .02]).
Among the 4 most prevalent CNVs, 3 (located at 22q11, 16p11, and 15q13) were flanked by known regions of segmental duplication and resulted most likely from a nonallelic homologous recombination mechanism. At the 2p16 locus, the NRXN1 gene was recurrently disrupted by a set of partially overlapping deletions spanning the promoter and first exons of neurexin 1α or the exons coding for the middle section of this protein, as well as for the proximal region of neurexin 1β. These rearrangements occurred in a region devoid of any segmental duplication and resulted from another mechanism distinct from a nonallelic homologous recombination mechanism.
Transmission and cosegregation in multiplex sibships
Among 27 families in which transmission was tested (69.2% of families with CNVs), 8 CNVs (located at 8p23, 15q11-q13, 15q13, 16p11, and 22q13) had occurred de novo (Table 3). The mean (SD) paternal age was not significantly different between families with de novo and inherited CNVs (27.2 [4.7] vs 30.7 [4.6] years; P = .19, Mann-Whitney test). In most families, CNVs were transmitted from an apparently nonaffected (although not clinically or neuropsychologically assessed) parent. This includes a partial duplication of the X-linked GRIA3 gene, present in a young male case with autism, which was inherited from the nonaffected mother. The 350-kb deletion located at 22q11 spanning the PRODH/DGCR6 locus was also transmitted in 11 of 11 tested cases. PRODH encodes for proline dehydrogenase, and PRODH deficiency is responsible for type 1 hyperprolinemia, a condition often associated with cognitive impairment and with psychotic symptoms.45 However, hemizygous deletion of the PRODH gene is insufficient per se to result in hyperprolinemia, as only 35% to 50% of cases with velocardiofacial syndrome, all bearing a single copy of PRODH, exhibit hyperprolinemia.45,48 Indeed, a reduction of more than 50% of the enzymatic activity is generally required to produce hyperprolinemia.45 Therefore, the presence of a mutation affecting enzyme activity49 on the second allele is necessary. To examine this issue, the remaining PRODH allele was sequenced in all cases bearing the 350-kb deletion, and the plasma proline level was assessed whenever possible. As summarized in Table 4, 14 of 15 cases harbored a genotype predicted to result in a reduction of at least 70% of enzymatic activity. Among 12 cases from whom the plasma proline level was assessed, 9 had mild to severe hyperprolinemia, and 3 had plasma proline levels at the upper boundary of normal values.
Cosegregation of the CNV with pathologic conditions was examined in 4 multiplex families in which DNA from affected siblings was available. In family 144 (Tables 3 and 4), the 2 sibs with schizophrenia or schizoaffective disorder harbored the PRODH/DGCR6 deletion. In family 11 695 (Table 3), the 2 MR sibs harbored the 2p16.3 deletion. In family 14 390 (Table 3), the 16p11 deletion was present in the proband with developmental language disorder but not in his sib with MR. In family 33 (Table 3), the 16p11 duplication was present in 2 sibs with schizophrenia and in a nonaffected sibling but was absent in a third sibling with schizoaffective disorder (eFigure 2).
Combining the results of the present study and previous findings, none of the observed rearrangements were disease specific, with the possible exception of the maternally derived 15q13 duplication associated with ASDs. The 22q1117 and 2p161 deletions were found in the 3 conditions, whereas the 22q13 deletion in 2 cases with ASDs had already been described in ASDs and in MR.4,18-20 The 16p11 and 8p23 rearrangements previously described in ASDs4,5 were found in cases with schizophrenia, and the 16p11 rearrangement was found in cases with MR. The Xp11.4 duplication spanning the TSPAN7 gene, previously described in MR and in ASDs,4,21 was found in a case with schizophrenia, as well as the 17q21 duplication previously described in a patient with MR.22 Two different-sized 15q13 duplications that included APBA2 were found in 1 case with ASDs and in 1 case with schizophrenia. A partial duplication of the GRIA3 gene, including the promoter region and the exons coding for the proximal region of GRIA3, was detected in a single case with autism. Although slightly different based on its size and the number of duplicated exons, this partial duplication is reminiscent of that recently reported in a patient with MR.23 At the 8p23 locus, gain and loss of material were found, as well as at the 16p11 and 17q21 loci, as recently described.22,24,25 This suggests that dosage-sensitive genes, whose expression is finely tuned, are located within these rearranged segments.
From a phenotypic viewpoint, 3 of 9 cases with schizophrenia bearing a candidate CNV had mild MR in an IQ assessment obtained after the onset of their psychotic symptoms (Table 3). No premorbid IQ was available for any case. Although postmorbid IQ likely constitutes an underestimation of the premorbid level of cognitive functioning in cases with schizophrenia, cognitive deficits manifest by severe learning disorders and failure to follow normal schooling were already noted in these 3 cases during childhood before the onset of their psychotic symptoms, supporting the comorbid diagnosis of MR and schizophrenia. In cases with potential MR (case 144.1 [Table 3] and cases 313 and 33.1 [Table 3]), psychotic features appeared at ages 25, 18, and 27 years, respectively, and included prominent positive symptoms such as persecutory delusions, thought insertions, delusions of being controlled, and auditory hallucinations with voices making insulting statements. The 3 cases had marked behavioral disorders such as aggressiveness and psychomotor agitation. Mood instability and suicidal ideation were present in case 144.1. The 3 cases were considered good responders to atypical neuroleptic drug therapy. Initial symptoms gradually declined, and the course of the disease was marked by social isolation, blunted affects, and loosening of associations. These cases are living in long-term institutions.
Except for 2 cases who had normal cognitive functioning (high-functioning autism), all tested CNV-bearing cases with autism had IQs in the range of MR, although case T35 had only mild cognitive dysfunction (Table 3). In 2 cases with high-functioning autism (cases 12 746 [Tables 3 and 4] and 44 813 [Table 3], aged 6 and 8 years, respectively), onset was in the first year of life, when the parents noticed few gestures, almost no babbling, and poor shifting gazes. Subsequently, the cases acquired spoken language, although with significant delay. They are able to carry on conversation, carry out commands, imitate, and dress and groom themselves. They participate in public school with adapted educative programs. However, they remain impaired in their communicative and social skills, and their use of language is often inappropriate. Both cases have developed ritualistic behaviors and show restricted patterns of interest.
In addition to the set of CNVs tested for recurrence in this study, 2 reciprocal rearrangements, previously unassociated with any psychiatric condition, were incidentally observed at 2 loci. Both were benign polymorphisms. A common CNV reciprocal to the expected one (ie, a 350-kb duplication) was found at the 22 q11 locus in 6 of 236 controls, as well as in 7 of 236 cases with schizophrenia, 4 of 260 cases with ASDs, and 9 of 247 cases with MR. Another overlapping reciprocal CNV (ie, a 490-kb duplication) was detected at the CHRNA7 locus located on chromosome 15q13.3. This CNV was present in 2 of 236 controls, in 1 of 236 cases with schizophrenia, in 1 of 260 cases with ASDs, and in 1 of 247 cases with MR and was unrelated to any pathologic condition (eTable 2).
After a first wave of CNV discovery by array-CGH analyses in neuropsychiatric disorders, this study for the first time (to our knowledge) examines the involvement of a limited number of candidate loci in large samples of cases with different clinical diagnoses. Two strengths of our study design are (1) the inclusion of controls carefully screened for the studied pathologic conditions and of series of cases mostly ascertained through consecutive admissions or consultations and, therefore, (2) the inclusion of cases belonging to simplex or multiplex families. Given the expected rarity of each variant, our first goal was not to test the association of every individual CNV with schizophrenia, ASDs, or MR but to determine whether these variants were collectively more frequent in cases with these diseases than among controls. This aim was successfully achieved, and we were able to obtain suggestive statistical significance for the association between the 350-kb deletion located at 22q11 and ASDs. This deleted segment, located within the chromosomal region deleted in velocardiofacial syndrome (a contiguous gene syndrome known to be associated with a high frequency of MR, ASDs, and psychosis), contained the 2 genes PRODH and DGCR6. Although we cannot exclude an involvement of DGCR6 in the neuropsychiatric phenotype of the cases bearing this CNV, previous work from our group strongly suggests that PRODH is the prime candidate.45 It was previously shown that hyperprolinemia, resulting from partial or total inactivation of this enzyme, (1) may lead to MR and autism in patients with type 1 hyperprolinemia,45 (2) is a risk factor for schizoaffective disorder,50 and (3) is inversely correlated with IQ in velocardiofacial syndrome.45 Herein, we show that all cases except 1 harboring this deletion were compound heterozygotes, also bearing mutations affecting enzymatic activity on the second allele. This resulted in a loss of at least 70% of the predicted PRODH residual activity in 14 of 15 assessed cases and resulted in hyperprolinemia in 9 of 12 assessed cases.
Second, we show that de novo CNVs and CNVs inherited from an apparently healthy parent can be found in cases. For transmitted CNVs, the mode of inheritance of the disease was recessive in some cases (eg, hyperprolinemia related to the 22q11 deletion) or implied the transmission of an X-linked gene (GRIA3) by a woman to her son. Consistent with findings in previous studies,4,8,26 the 16p11 rearrangements were inherited from an apparently nonaffected parent in 3 families. These CNVs, whose estimated frequency in the Icelandic population was 5 per 18 834 (0.03%) for the duplication and 2 per 18 834 (0.01%) for the deletion,25 should be considered risk factors rather than fully causative variations. The presence of affected siblings that do not share the CNV, already noted in a previous study,26 does not necessarily rule out the causative implication of these CNVs but raises the question of intrafamilial genetic heterogeneity. This hypothesis, which is plausible for these frequent disorders that are often characterized by assortative mating, remains speculative because the parents and their relatives were not psychiatrically or cognitively assessed in these families.
Third and most important, our study confirms and extends recent evidence suggesting that many candidate CNVs are not disease specific but are involved in the expression of different behavioral phenotypes, including MR, ASDs, and schizophrenia. This implies the existence of shared biologic pathways in these 3 neurodevelopmental conditions. These pathways chiefly affect synapse formation and maintenance, as well as neurotransmission (with a special emphasis on glutamate and γ-aminobutyric acid). The dysfunction of specific neuronal networks underlying the particular symptoms of each clinical condition most likely depends on additional genetics, epigenetics, and environmental factors that remain to be characterized. From a clinical point of view, despite the diversity of categorical diagnoses, many cases harboring these CNVs shared some clinical features: one-third of cases with schizophrenia and 83.3% of cases with autism having CNVs had a level of cognitive functioning in the range of MR. This is in accord with previous studies showing that point prevalence of schizophrenia is increased by a factor of 3 in cases with intellectual disabilities51 and that 50% of cases with autism have MR.52 However, the following 2 caveats should be noted: (1) because attention and communication are markedly impaired in children with autism, assessment of their IQs (even performance IQs in nonverbal cases) is unreliable, and (2) these results were not obtained in a single community–based population but in 3 disease groups ascertained according to different schemes, a factor whose effect is difficult to appreciate but which is likely to have implications related to the phenotypic severity in these cases.
Fourth, targeted procedures for CNV analysis such as the QMPSF method is a cost-effective alternative to array-CGH for the screening of candidate loci in large case-control cohorts. We plan to conduct extensive resequencing of these candidate genes to further validate their role in these conditions.
Since our submission of this article for publication, additional studies9,11,53,54 have been published documenting shared CNVs between MR, ASDs, and schizophrenia.
Correspondence: Dominique Campion, MD, PhD, Institut National de la Santé et de la Recherche Médicale, Unité 614, Institut Hospitalo-Universitaire de Recherche Biomédicale, 22 Blvd Gambetta, 76000 Rouen, France (dominique.campion@univ-rouen.fr).
Submitted for Publication: August 5, 2008; final revision received February 6, 2009; accepted February 23, 2009.
Author Contributions: Dr Campion had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This study was supported by the Fondation de France, by Collaborative Biologic Resources From the Autism Foundation (RBCFA), and by the French Autism Foundation. Dr Guilmatre received a fellowship from Region Haute Normandie, and Dr Mosca received a fellowship from the Académie Nationale de Médecine.
Role of the Sponsors: We acknowledge the usefulness of the available resources from the RBCFA and from the families involved in the RBCFA. RBCFA is a program of the French Autism Foundation, which is recognized to be of public usefulness, was created by parents of autistic patients, and whose scientific director is Sylvain Briault, MD, PhD, researcher at the INSERM.
Additional Contributions: Technical support for the transcriptomic platform was provided by OUEST Genopole and by Genethon. We thank our colleagues who helped to identify patients, as well as the patients and their families for their participation.
1.Friedman
JMBaross
ADelaney
ADAlly
AArbour
LArmstrong
LAsano
JBailey
DKBarber
SBirch
PBrown-John
MCao
MChan
SCharest
DLFarnoud
NFernandes
NFlibotte
SGo
AGibson
WTHolt
RAJones
SJKennedy
GCKrzywinski
MLanglois
SLi
HI McGillivray
BCNayar
TPugh
TJRajcan-Separovic
ESchein
JESchnerch
ASiddiqui
AVan Allen
MIWilson
GYong
SLZahir
FEydoux
PMarra
MA Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation [published correction appears in
Am J Hum Genet. 2006;79(6):1135].
Am J Hum Genet 2006;79
(3)
500- 513
PubMedGoogle ScholarCrossref 2.Froyen
GVan Esch
HBauters
MHollanders
KFrints
SGVermeesch
JRDevriendt
KFryns
JPMarynen
P Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of
XLMR genes.
Hum Mutat 2007;28
(10)
1034- 1042
PubMedGoogle ScholarCrossref 3.Menten
BMaas
NThienpont
BBuysse
KVandesompele
JMelotte
Cde Ravel
TVan Vooren
SBalikova
IBackx
LJanssens
SDe Paepe
ADe Moor
BMoreau
YMarynen
PFryns
JPMortier
GDevriendt
KSpeleman
FVermeesch
JR Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports.
J Med Genet 2006;43
(8)
625- 633
PubMedGoogle ScholarCrossref 4.Marshall
CRNoor
AVincent
JBLionel
ACFeuk
LSkaug
JShago
MMoessner
RPinto
DRen
YThiruvahindrapduram
BFiebig
ASchreiber
SFriedman
JKetelaars
CEVos
YJFicicioglu
CKirkpatrick
SNicolson
RSloman
LSummers
AGibbons
CATeebi
AChitayat
DWeksberg
RThompson
AVardy
CCrosbie
VLuscombe
SBaatjes
RZwaigenbaum
LRoberts
WFernandez
BSzatmari
PScherer
SW Structural variation of chromosomes in autism spectrum disorder.
Am J Hum Genet 2008;82
(2)
477- 488
PubMedGoogle ScholarCrossref 5.Sebat
JLakshmi
BMalhotra
DTroge
JLese-Martin
CWalsh
TYamrom
BYoon
SKrasnitz
AKendall
JLeotta
APai
DZhang
RLee
YHHicks
JSpence
SJLee
ATPuura
KLehtimäki
TLedbetter
DGregersen
PKBregman
JSutcliffe
JSJobanputra
VChung
WWarburton
DKing
MCSkuse
DGeschwind
DHGilliam
TCYe
KWigler
M Strong association of de novo copy number mutations with autism.
Science 2007;316
(5823)
445- 449
PubMedGoogle ScholarCrossref 6.Christian
SLBrune
CWSudi
JKumar
RALiu
SKaramohamed
SBadner
JAMatsui
SConroy
J McQuaid
DGergel
JHatchwell
EGilliam
TCGershon
ESNowak
NJDobyns
WBCook
EH
Jr Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder.
Biol Psychiatry 2008;63
(12)
1111- 1117
PubMedGoogle ScholarCrossref 7.Szatmari
PPaterson
ADZwaigenbaum
LRoberts
WBrian
JLiu
XQVincent
JBSkaug
JLThompson
APSenman
LFeuk
LQian
CBryson
SEJones
MBMarshall
CRScherer
SWVieland
VJBartlett
CMangin
LVGoedken
RSegre
APericak-Vance
MACuccaro
MLGilbert
JRWright
HHAbramson
RKBetancur
CBourgeron
TGillberg
CLeboyer
MBuxbaum
JDDavis
KLHollander
ESilverman
JMHallmayer
JLotspeich
LSutcliffe
JSHaines
JLFolstein
SEPiven
JWassink
THSheffield
VGeschwind
DHBucan
MBrown
WTCantor
RMConstantino
JNGilliam
TCHerbert
MLajonchere
CLedbetter
DHLese-Martin
CMiller
JNelson
SSamango-Sprouse
CASpence
SState
MTanzi
RECoon
HDawson
GDevlin
BEstes
AFlodman
PKlei
L McMahon
WMMinshew
NMunson
JKorvatska
ERodier
PMSchellenberg
GDSmith
MSpence
MAStodgell
CTepper
PGWijsman
EMYu
CERogé
BMantoulan
CWittemeyer
KPoustka
AFelder
BKlauck
SMSchuster
CPoustka
FBölte
SFeineis-Matthews
SHerbrecht
ESchmötzer
GTsiantis
JPapanikolaou
KMaestrini
EBacchelli
EBlasi
FCarone
SToma
CVan Engeland
Hde Jonge
MKemner
CKoop
FLangemeijer
MHijmans
CStaal
WGBaird
GBolton
PFRutter
MLWeisblatt
EGreen
JAldred
CWilkinson
JAPickles
ALe Couteur
ABerney
T McConachie
HBailey
AJFrancis
KHoneyman
GHutchinson
AParr
JRWallace
SMonaco
APBarnby
GKobayashi
KLamb
JASousa
ISykes
NCook
EHGuter
SJLeventhal
BLSalt
JLord
CCorsello
CHus
VWeeks
DEVolkmar
FTauber
MFombonne
EShih
AMeyer
KJAutism Genome Project Consortium, Mapping autism risk loci using genetic linkage and chromosomal rearrangements [published correction appears in
Nat Genet. 2007;39(10):1285].
Nat Genet 2007;39
(3)
319- 328
PubMedGoogle ScholarCrossref 8.Walsh
T McClellan
JM McCarthy
SEAddington
AMPierce
SBCooper
GMNord
ASKusenda
MMalhotra
DBhandari
AStray
SMRippey
CFRoccanova
PMakarov
VLakshmi
BFindling
RLSikich
LStromberg
TMerriman
BGogtay
NButler
PEckstrand
KNoory
LGochman
PLong
RChen
ZDavis
SBaker
CEichler
EEMeltzer
PSNelson
SFSingleton
ABLee
MKRapoport
JLKing
MCSebat
J Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.
Science 2008;320
(5875)
539- 543
PubMedGoogle ScholarCrossref 9.International Schizophrenia Consortium, Rare chromosomal deletions and duplications increase risk of schizophrenia.
Nature 2008;455
(7210)
237- 241
PubMedGoogle ScholarCrossref 10.Kirov
GGumus
DChen
WNorton
NGeorgieva
LSari
MO’Donovan
MCErdogan
FOwen
MJRopers
HHUllmann
R Comparative genome hybridization suggests a role for
NRXN1 and
APBA2 in schizophrenia.
Hum Mol Genet 2008;17
(3)
458- 465
PubMedGoogle ScholarCrossref 11.Xu
BRoos
JLLevy
Svan Rensburg
EJGogos
JAKarayiorgou
M Strong association of de novo copy number mutations with sporadic schizophrenia.
Nat Genet 2008;40
(7)
880- 885
PubMedGoogle ScholarCrossref 13.Fyer
AJEJManuzza
SKlein
DF Schedule for Affective Disorders and Schizophrenia. Paris, France INSERM Ed1989;
14.Lord
CRutter
MLe Couteur
A Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.
J Autism Dev Disord 1994;24
(5)
659- 685
PubMedGoogle ScholarCrossref 15.Lord
CRisi
SLambrecht
LCook
EH
JrLeventhal
BLDiLavore
PCPickles
ARutter
M The Autism Diagnostic Observation Schedule–Generic: a standard measure of social and communication deficits associated with the spectrum of autism.
J Autism Dev Disord 2000;30
(3)
205- 223
PubMedGoogle ScholarCrossref 16.Schopler
EReichler
RJDeVellis
RFDaly
K Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS).
J Autism Dev Disord 1980;10
(1)
91- 103
PubMedGoogle ScholarCrossref 18.Durand
CMBetancur
CBoeckers
TMBockmann
JChaste
PFauchereau
FNygren
GRastam
MGillberg
ICAnckarsäter
HSponheim
EGoubran-Botros
HDelorme
RChabane
NMouren-Simeoni
MCde Mas
PBieth
ERogé
BHéron
DBurglen
LGillberg
CLeboyer
MBourgeron
T Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders.
Nat Genet 2007;39
(1)
25- 27
PubMedGoogle ScholarCrossref 19.Moessner
RMarshall
CRSutcliffe
JSSkaug
JPinto
DVincent
JZwaigenbaum
LFernandez
BRoberts
WSzatmari
PScherer
SW Contribution of
SHANK3 mutations to autism spectrum disorder.
Am J Hum Genet 2007;81
(6)
1289- 1297
PubMedGoogle ScholarCrossref 20.Wilson
HLWong
ACShaw
SRTse
WYStapleton
GAPhelan
MCHu
SMarshall
J McDermid
HE Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of
SHANK3/PROSAP2 in the major neurological symptoms.
J Med Genet 2003;40
(8)
575- 584
PubMedGoogle ScholarCrossref 21.Tzschach
AChen
WErdogan
FHoeller
ARopers
HHCastellan
CUllmann
RSchinzel
A Characterization of interstitial Xp duplications in two families by tiling path array CGH.
Am J Med Genet A 2008;146A
(2)
197- 203
PubMedGoogle ScholarCrossref 22.Kirchhoff
MBisgaard
AMDuno
MHansen
FJSchwartz
M A 17q21.31 microduplication, reciprocal to the newly described 17q21.31 microdeletion, in a girl with severe psychomotor developmental delay and dysmorphic craniofacial features.
Eur J Med Genet 2007;50
(4)
256- 263
PubMedGoogle ScholarCrossref 23.Chiyonobu
THayashi
SKobayashi
KMorimoto
MMiyanomae
YNishimura
ANishimoto
AIto
CImoto
ISugimoto
TJia
ZInazawa
JToda
T Partial tandem duplication of
GRIA3 in a male with mental retardation.
Am J Med Genet A 2007;143A
(13)
1448- 1455
PubMedGoogle ScholarCrossref 24.Shaw-Smith
CPittman
AMWillatt
LMartin
HRickman
LGribble
SCurley
RCumming
SDunn
CKalaitzopoulos
DPorter
KPrigmore
EKrepischi-Santos
ACVarela
MCKoiffmann
CPLees
AJRosenberg
CFirth
HVde Silva
RCarter
NP Microdeletion encompassing
MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability.
Nat Genet 2006;38
(9)
1032- 1037
PubMedGoogle ScholarCrossref 25.Weiss
LAShen
YKorn
JMArking
DEMiller
DTFossdal
RSaemundsen
EStefansson
HFerreira
MAGreen
TPlatt
OSRuderfer
DMWalsh
CAAltshuler
DChakravarti
ATanzi
REStefansson
KSantangelo
SLGusella
JFSklar
PWu
BLDaly
MJAutism Consortium, Association between microdeletion and microduplication at 16p11.2 and autism.
N Engl J Med 2008;358
(7)
667- 675
PubMedGoogle ScholarCrossref 26.Kumar
RAKaraMohamed
SSudi
JConrad
DFBrune
CBadner
JAGilliam
TCNowak
NJCook
EH
JrDobyns
WBChristian
SL Recurrent 16p11.2 microdeletions in autism.
Hum Mol Genet 2008;17
(4)
628- 638
PubMedGoogle ScholarCrossref 27.Kim
HGKishikawa
SHiggins
AWSeong
ISDonovan
DJShen
YLally
EWeiss
LANajm
JKutsche
KDescartes
MHolt
LBraddock
STroxell
RKaplan
LVolkmar
FKlin
ATsatsanis
KHarris
DJNoens
IPauls
DLDaly
MJMacDonald
MEMorton
CCQuade
BJGusella
JF Disruption of neurexin 1 associated with autism spectrum disorder.
Am J Hum Genet 2008;82
(1)
199- 207
PubMedGoogle ScholarCrossref 28.Zahir
FRBaross
ADelaney
ADEydoux
PFernandes
NDPugh
TMarra
MAFriedman
JM A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of
NRXN1α.
J Med Genet 2008;45
(4)
239- 243
PubMedGoogle ScholarCrossref 29.Dijkhuizen
Tvan Essen
Tvan der Vlies
PVerheij
JBSikkema-Raddatz
Bvan der Veen
AYGerssen-Schoorl
KBBuys
CHKok
K FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of
CNTN4 and
CRBN contributes to mental retardation in 3pter deletions.
Am J Med Genet A 2006;140
(22)
2482- 2487
PubMedGoogle ScholarCrossref 30.Roohi
JMontagna
CTegay
DHPalmer
LEDeVincent
CPomeroy
JCChristian
SLNowak
NHatchwell
E Disruption of contactin 4 in three subjects with autism spectrum disorder.
J Med Genet 2009;46
(3)
176- 182
Google ScholarCrossref 31.Meins
MHagh
JKGerresheim
FEinhoff
EOlschewski
HStrehl
HEpplen
JT Novel case of dup(3q) syndrome due to a de novo interstitial duplication 3q24-q26.31 with minimal overlap to the dup(3q) critical region.
Am J Med Genet A 2005;132A
(1)
84- 89
PubMedGoogle ScholarCrossref 32.Kakinuma
HOzaki
MSato
HTakahashi
H Variation in GABA-A subunit gene copy number in an autistic patient with mosaic 4 p duplication (p12p16).
Am J Med Genet B Neuropsychiatr Genet 2008;147B
(6)
973- 975
Google ScholarCrossref 33.Friedman
JIVrijenhoek
TMarkx
SJanssen
IMvan der Vliet
WAFaas
BHKnoers
NVCahn
WKahn
RSEdelmann
LDavis
KLSilverman
JMBrunner
HGvan Kessel
AGWijmenga
COphoff
RAVeltman
JA
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy.
Mol Psychiatry 2008;13
(3)
261- 266
PubMedGoogle ScholarCrossref 34.Klopocki
EFiebig
BRobinson
PTönnies
HErdogan
FRopers
HHMundlos
SUllmann
R A novel 8 Mb interstitial deletion of chromosome 8p12-p21.2.
Am J Med Genet A 2006;140
(8)
873- 877
PubMedGoogle ScholarCrossref 35.Bolton
PFDennis
NRBrowne
CEThomas
NSVeltman
MWThompson
RJJacobs
P The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders.
Am J Med Genet 2001;105
(8)
675- 685
PubMedGoogle ScholarCrossref 36.Cook
EH
JrLindgren
VLeventhal
BLCourchesne
RLincoln
AShulman
CLord
CCourchesne
E Autism or atypical autism in maternally but not paternally derived proximal 15q duplication.
Am J Hum Genet 1997;60
(4)
928- 934
PubMedGoogle Scholar 37.Sharp
AJMefford
HCLi
KBaker
CSkinner
CStevenson
RESchroer
RJNovara
FDe Gregori
MCiccone
RBroomer
ACasuga
IWang
YXiao
CBarbacioru
CGimelli
GBernardina
BDTorniero
CGiorda
RRegan
RMurday
VMansour
SFichera
MCastiglia
LFailla
PVentura
MJiang
ZCooper
GMKnight
SJRomano
CZuffardi
OChen
CSchwartz
CEEichler
EE A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures.
Nat Genet 2008;40
(3)
322- 328
PubMedGoogle ScholarCrossref 38.Chocholska
SRossier
EBarbi
GKehrer-Sawatzki
H Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers.
Am J Med Genet A 2006;140
(6)
604- 610
PubMedGoogle ScholarCrossref 39.Kent
LEmerton
JBhadravathi
VWeisblatt
EPasco
GWillatt
LR McMahon
RYates
JR X-linked ichthyosis (steroid sulphatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits.
J Med Genet 2008;45
(8)
519- 524
Google ScholarCrossref 40.Lawson-Yuen
ASaldivar
JSSommer
SPicker
J Familial deletion within
NLGN4 associated with autism and Tourette syndrome.
Eur J Hum Genet 2008;16
(5)
614- 618
PubMedGoogle ScholarCrossref 41.Macarov
MZeigler
MNewman
JPStrich
DSury
VTennenbaum
AMeiner
V Deletions of
VCX-A and
NLGN4: a variable phenotype including normal intellect.
J Intellect Disabil Res 2007;51
(pt 5)
329- 333
PubMedGoogle ScholarCrossref 42.Jin
HGardner
RJViswesvaraiah
RMuntoni
FRoberts
RG Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21.3 mental retardation.
Eur J Hum Genet 2000;8
(2)
87- 94
PubMedGoogle ScholarCrossref 43.del Gaudio
DFang
PScaglia
FWard
PACraigen
WJGlaze
DGNeul
JLPatel
ALee
JAIrons
MBerry
SAPursley
AAGrebe
TAFreedenberg
DMartin
RAHsich
GEKhera
JRFriedman
NRZoghbi
HYEng
CMLupski
JRBeaudet
ALCheung
SWRoa
BB Increased
MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males.
Genet Med 2006;8
(12)
784- 792
PubMedGoogle ScholarCrossref 44.Casilli
FDi Rocco
ZCGad
STournier
IStoppa-Lyonnet
DFrebourg
TTosi
M Rapid detection of novel
BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.
Hum Mutat 2002;20
(3)
218- 226
PubMedGoogle ScholarCrossref 45.Raux
GBumsel
EHecketsweiler
Bvan Amelsvoort
TZinkstok
JManouvrier-Hanu
SFantini
CBrévière
GMDi Rosa
GPustorino
GVogels
ASwillen
ALegallic
SBou
JOpolczynski
GDrouin-Garraud
VLemarchand
MPhilip
NGérard-Desplanches
ACarlier
MPhilippe
ANolen
MCHeron
DSarda
PLacombe
DCoizet
CAlembik
YLayet
VAfenjar
AHannequin
DDemily
CPetit
MThibaut
FFrebourg
TCampion
D Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome.
Hum Mol Genet 2007;16
(1)
83- 91
PubMedGoogle ScholarCrossref 46.Ohtsuki
TTanaka
SIshiguro
HNoguchi
EArinami
TTanabe
EYara
KOkubo
TTakahashi
SMatsuura
MSakai
TMuto
MKojima
TMatsushima
EToru
MInada
T Failure to find association between
PRODH deletion and schizophrenia.
Schizophr Res 2004;67
(1)
111- 113
PubMedGoogle ScholarCrossref 47.Zogopoulos
GHa
KCNaqib
FMoore
SKim
HMontpetit
ARobidoux
FLaflamme
PCotterchio
MGreenwood
CScherer
SWZanke
BHudson
TJBader
GDGallinger
S Germ-line DNA copy number variation frequencies in a large North American population.
Hum Genet 2007;122
(3-4)
345- 353
PubMedGoogle ScholarCrossref 48.Goodman
BKRutberg
JLin
WWPulver
AEThomas
GH Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome.
J Inherit Metab Dis 2000;23
(8)
847- 848
PubMedGoogle ScholarCrossref 49.Bender
HUAlmashanu
SSteel
GHu
CALin
WWWillis
APulver
AValle
D Functional consequences of
PRODH missense mutations.
Am J Hum Genet 2005;76
(3)
409- 420
PubMedGoogle ScholarCrossref 50.Jacquet
HDemily
CHouy
EHecketsweiler
BBou
JRaux
GLerond
JAllio
GHaouzir
STillaux
ABellegou
CFouldrin
GDelamillieure
PMénard
JFDollfus
SD’Amato
TPetit
MThibaut
FFrébourg
TCampion
D Hyperprolinemia is a risk factor for schizoaffective disorder.
Mol Psychiatry 2005;10
(5)
479- 485
PubMedGoogle ScholarCrossref 51.Cooper
SASmiley
EMorrison
JAllan
LWilliamson
AFinlayson
JJackson
AMantry
D Psychosis and adults with intellectual disabilities: prevalence, incidence, and related factors.
Soc Psychiatry Psychiatr Epidemiol 2007;42
(7)
530- 536
PubMedGoogle ScholarCrossref 53.Stefansson
HRujescu
DCichon
SPietiläinen
OPIngason
ASteinberg
SFossdal
RSigurdsson
ESigmundsson
TBuizer-Voskamp
JEHansen
TJakobsen
KDMuglia
PFrancks
CMatthews
PMGylfason
AHalldorsson
BVGudbjartsson
DThorgeirsson
TESigurdsson
AJonasdottir
AJonasdottir
ABjornsson
AMattiasdottir
SBlondal
THaraldsson
MMagnusdottir
BBGiegling
IMöller
HJHartmann
AShianna
KVGe
DNeed
ACCrombie
CFraser
GWalker
NLonnqvist
JSuvisaari
JTuulio-Henriksson
APaunio
TToulopoulou
TBramon
EDi Forti
MMurray
RRuggeri
MVassos
ETosato
SWalshe
MLi
TVasilescu
CMühleisen
TWWang
AGUllum
HDjurovic
SMelle
IOlesen
J Kiemeney
LAFranke
BSabatti
CFreimer
NBGulcher
JRThorsteinsdottir
UKong
AAndreassen
OAOphoff
RAGeorgi
ARietschel
MWerge
TPetursson
HGoldstein
DBNöthen
MMPeltonen
LCollier
DASt Clair
DStefansson
K Large recurrent microdeletions associated with schizophrenia.
Nature 2008;455
(7210)
232- 236
PubMedGoogle ScholarCrossref 54.Mefford
HCSharp
AJBaker
CItsara
AJiang
ZBuysse
KHuang
SMaloney
VKCrolla
JABaralle
DCollins
AMercer
CNorga
Kde Ravel
TDevriendt
KBongers
EMde Leeuw
NReardon
WGimelli
SBena
FHennekam
RCMale
AGaunt
LClayton-Smith
JSimonic
IPark
SMMehta
SGNik-Zainal
SWoods
CGFirth
HVParkin
GFichera
MReitano
SLo Giudice
MLi
KECasuga
IBroomer
AConrad
BSchwerzmann
MRäber
LGallati
SStriano
PCoppola
ATolmie
JLTobias
ESLilley
CArmengol
LSpysschaert
YVerloo
PDe Coene
AGoossens
LMortier
GSpeleman
Fvan Binsbergen
ENelen
MRHochstenbach
RPoot
MGallagher
LGill
M McClellan
JKing
MCRegan
RSkinner
CStevenson
REAntonarakis
SEChen
CEstivill
XMenten
BGimelli
GGribble
SSchwartz
SSutcliffe
JSWalsh
TKnight
SJSebat
JRomano
CSchwartz
CEVeltman
JAde Vries
BBVermeesch
JRBarber
JCWillatt
LTassabehji
MEichler
EE Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes.
N Engl J Med 2008;359
(16)
1685- 1699
PubMedGoogle ScholarCrossref